Takeda looks to further its investment in its European operations

By Catherine Sturman
Whilst the threat of Brexit is seeing a large number of companies moving their operations out of the UK and Europe altogether, Takeda is looking to plac...

Whilst the threat of Brexit is seeing a large number of companies moving their operations out of the UK and Europe altogether, Takeda is looking to place further investment. The pharmaceutical company are looking to build a new manufacturing facility in Ireland, providing over 40 jobs in Dublin.

Costing up to €100 million, the manufacturing facility will be over 32,000 sq ft and encompass two storeys. It will be situated next to an existing facility, located at Grange Castle Business Park. The manufacturing plant will be committed to the ongoing development of oncology drug Ninlaro.

"Ninlaro has the potential to help European patients with relapsed multiple myeloma by removing some of the barriers that can stand in the way of optimal treatment,” commented Takeda President Christophe Bianchi.

Related stories

“With Ninlaro, our hope is that many patients will be able to continue therapy until disease progression."

The news also is highly significant, given that another pharmaceutical giant, AstraZeneca has also placed investment in a new manufacturing plant in the UK for the development of prostate cancer drug Zoladex.

However, the company is also looking at further areas of future investment. Russia, for example, has become a hot contender, where Takeda will no doubt be looking at furthering their manufacturing capabilities through new and existing partnerships.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare